Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy – current evidence and future trends

Trastuzumab Therapy ◽

Author Correction to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy

PharmacoEconomics ◽

10.1007/s40273-018-0634-5 ◽

2018 ◽

Vol 36 (4) ◽

pp. 505-505

Author(s):

Amir Ansaripour ◽

Carin A. Uyl-de Groot ◽

W. Ken Redekop

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Scenario Analysis ◽

Treatment Strategy ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Optimal Treatment Strategy ◽

Trastuzumab use at relapse after adjuvant trastuzumab therapy in HER2-positive breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.575 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 575-575 ◽

Cited By ~ 1

Author(s):

I. Lang ◽

R. Bell ◽

F. Feng ◽

R. I. Lopez ◽

J. Jassem ◽

...

Keyword(s):

Breast Cancer ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Optimality, Future and Terminal Costs: Comment on “Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran”

PharmacoEconomics ◽

10.1007/s40273-018-0621-x ◽

2018 ◽

Vol 36 (3) ◽

pp. 383-384

Author(s):

Noga Gershon ◽

Yakir Berchenko

Keyword(s):

Breast Cancer ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Adjuvant Trastuzumab Therapy In Her2-Positive Breast Cancer Patients: A Meta-Analysis Of Published Randomized Trials

Value in Health ◽

10.1016/j.jval.2013.03.622 ◽

2013 ◽

Vol 16 (3) ◽

pp. A128

Author(s):

Y. Xia ◽

B. Bian ◽

E. Costea ◽

C.M. Kelton ◽

J.J. Guo

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Randomized Trials ◽

Meta Analysis ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade During HER2-Positive Breast Cancer Progression

SSRN Electronic Journal ◽

10.2139/ssrn.3155728 ◽

2018 ◽

Author(s):

Marie-Anne Goyette ◽

Sttphanie Duhamel ◽

LLo Aubert ◽

Ariane Pelletier ◽

Paul Savage ◽

...

Keyword(s):

Breast Cancer ◽

Tyrosine Kinase ◽

Cancer Progression ◽

Receptor Tyrosine Kinase ◽

Breast Cancer Progression ◽

Her2 Positive ◽

Metastatic Cascade ◽

PCN61 COST-EFFECTIVENESS OF 1-YEAR ADJUVANT TRASTUZUMAB THERAPY FOR EARLY STAGE OF HER2-POSITIVE BREAST CANCER

Value in Health ◽

10.1016/j.jval.2011.02.916 ◽

2011 ◽

Vol 14 (3) ◽

pp. A165

Author(s):

T.T.T. Nguyen ◽

R. Yagudina ◽

A.U. Kulikov

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Stage ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Cost-Effectiveness Analysis of 1-Year Adjuvant Trastuzumab Therapy of Early-Stage Her2-Positive Breast Cancer

Value in Health ◽

10.1016/j.jval.2014.08.107 ◽

2014 ◽

Vol 17 (7) ◽

pp. A735 ◽

Cited By ~ 1

Author(s):

Nguyen TTC ◽

Nguyen TTT

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Stage ◽

Cost Effectiveness Analysis ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Effectiveness Analysis ◽

The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression

Cell Reports ◽

10.1016/j.celrep.2018.04.019 ◽

2018 ◽

Vol 23 (5) ◽

pp. 1476-1490 ◽

Cited By ~ 44

Author(s):

Marie-Anne Goyette ◽

Stéphanie Duhamel ◽

Léo Aubert ◽

Ariane Pelletier ◽

Paul Savage ◽

...

Keyword(s):

Breast Cancer ◽

Tyrosine Kinase ◽

Cancer Progression ◽

Receptor Tyrosine Kinase ◽

Breast Cancer Progression ◽

Her2 Positive ◽

Metastatic Cascade ◽

Response to ‘Comment on ‘‘Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”’

PharmacoEconomics ◽

10.1007/s40273-018-0620-y ◽

2018 ◽

Vol 36 (3) ◽

pp. 381-382

Author(s):

Amir Ansaripour ◽

Carin A. Uyl-de Groot ◽

W. Ken Redekop

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Scenario Analysis ◽

Treatment Strategy ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Optimal Treatment Strategy ◽

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy

PharmacoEconomics ◽

10.1007/s40273-017-0557-6 ◽

2017 ◽

Vol 36 (1) ◽

pp. 91-103 ◽

Cited By ~ 11

Author(s):

Amir Ansaripour ◽

Carin A. Uyl-de Groot ◽

W. Ken Redekop

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Scenario Analysis ◽

Treatment Strategy ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Optimal Treatment Strategy ◽